Parotid gland tumors: Preliminary data for the value of FDG PET/CT diagnostic parameters

David Hadiprodjo, Timothy Ryan, Minh Tam Truong, Gustavo Mercier, Rathan M. Subramaniam

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

OBJECTIVE. The purpose of this article is to establish 18F-FDG metabolic imaging parameters to differentiate benign and malignant tumors of the parotid gland. MATERIALS AND METHODS. Forty-nine patients with increased FDG uptake in the parotid gland were selected for the study group (29 men and 20 women; mean age, 63.14 ± 12.32 years). Another 49 patients without head and neck malignancies were selected as the control group (24 men and 25 women; mean age, 65.80 ± 11.51 years); they did not have a parotid lesion or increased FDG uptake in the parotid gland. Maximum standardized uptake value (SUV max) was obtained for all patients. Metabolic tumor volume and total glycolytic activity were measured in patients with a discrete parotid lesion (n = 24). Nonparameteric Student t test (Mann- Whitney U test) was performed for between-group analysis. RESULTS. The median SUV max of the increased diffuse uptake (2.55; interquartile range [IQR], 1.03-4.07) was significantly lower than the median SUV max of tumors (8.48; IQR, 1.46-15.5) (p < 0.01). The median SUV max of malignant tumors (11.8; IQR, 4.45-19.15) was significantly (p < 0.05) higher than that of benign tumors (6.4; IQR, 3.4-9.0). There was significant difference (p = 0.003) in the median metabolic tumor volume for malignant tumors (8.9; IQR, 5.1-25.5) and benign tumors or lesions (1.4; IQR, 1.00-2.9). Similar results were found for total glycolytic activity for malignant tumors (67.9; IQR, 24.2-137.6) and benign tumors or lesions (8.4; IQR, 3.9-13.6) (p = 0.002). CONCLUSION. FDG PET/CT SUV max, metabolic tumor volume, and total glycolytic activity are imaging parameters to differentiate benign and malignant tumors of the parotid gland.

Original languageEnglish (US)
JournalAmerican Journal of Roentgenology
Volume198
Issue number2
DOIs
StatePublished - Feb 1 2012

Fingerprint

Parotid Gland
Neoplasms
Tumor Burden
Fluorodeoxyglucose F18
Nonparametric Statistics
Neck
Head
Students
Control Groups

Keywords

  • FDG
  • Metabolic tumor volume
  • Parotid gland
  • Tumors

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Parotid gland tumors : Preliminary data for the value of FDG PET/CT diagnostic parameters. / Hadiprodjo, David; Ryan, Timothy; Truong, Minh Tam; Mercier, Gustavo; Subramaniam, Rathan M.

In: American Journal of Roentgenology, Vol. 198, No. 2, 01.02.2012.

Research output: Contribution to journalArticle

Hadiprodjo, David ; Ryan, Timothy ; Truong, Minh Tam ; Mercier, Gustavo ; Subramaniam, Rathan M. / Parotid gland tumors : Preliminary data for the value of FDG PET/CT diagnostic parameters. In: American Journal of Roentgenology. 2012 ; Vol. 198, No. 2.
@article{5196b679d4344f7391ad9e1fda71b897,
title = "Parotid gland tumors: Preliminary data for the value of FDG PET/CT diagnostic parameters",
abstract = "OBJECTIVE. The purpose of this article is to establish 18F-FDG metabolic imaging parameters to differentiate benign and malignant tumors of the parotid gland. MATERIALS AND METHODS. Forty-nine patients with increased FDG uptake in the parotid gland were selected for the study group (29 men and 20 women; mean age, 63.14 ± 12.32 years). Another 49 patients without head and neck malignancies were selected as the control group (24 men and 25 women; mean age, 65.80 ± 11.51 years); they did not have a parotid lesion or increased FDG uptake in the parotid gland. Maximum standardized uptake value (SUV max) was obtained for all patients. Metabolic tumor volume and total glycolytic activity were measured in patients with a discrete parotid lesion (n = 24). Nonparameteric Student t test (Mann- Whitney U test) was performed for between-group analysis. RESULTS. The median SUV max of the increased diffuse uptake (2.55; interquartile range [IQR], 1.03-4.07) was significantly lower than the median SUV max of tumors (8.48; IQR, 1.46-15.5) (p < 0.01). The median SUV max of malignant tumors (11.8; IQR, 4.45-19.15) was significantly (p < 0.05) higher than that of benign tumors (6.4; IQR, 3.4-9.0). There was significant difference (p = 0.003) in the median metabolic tumor volume for malignant tumors (8.9; IQR, 5.1-25.5) and benign tumors or lesions (1.4; IQR, 1.00-2.9). Similar results were found for total glycolytic activity for malignant tumors (67.9; IQR, 24.2-137.6) and benign tumors or lesions (8.4; IQR, 3.9-13.6) (p = 0.002). CONCLUSION. FDG PET/CT SUV max, metabolic tumor volume, and total glycolytic activity are imaging parameters to differentiate benign and malignant tumors of the parotid gland.",
keywords = "FDG, Metabolic tumor volume, Parotid gland, Tumors",
author = "David Hadiprodjo and Timothy Ryan and Truong, {Minh Tam} and Gustavo Mercier and Subramaniam, {Rathan M.}",
year = "2012",
month = "2",
day = "1",
doi = "10.2214/AJR.11.7172",
language = "English (US)",
volume = "198",
journal = "American Journal of Roentgenology",
issn = "0361-803X",
publisher = "American Roentgen Ray Society",
number = "2",

}

TY - JOUR

T1 - Parotid gland tumors

T2 - Preliminary data for the value of FDG PET/CT diagnostic parameters

AU - Hadiprodjo, David

AU - Ryan, Timothy

AU - Truong, Minh Tam

AU - Mercier, Gustavo

AU - Subramaniam, Rathan M.

PY - 2012/2/1

Y1 - 2012/2/1

N2 - OBJECTIVE. The purpose of this article is to establish 18F-FDG metabolic imaging parameters to differentiate benign and malignant tumors of the parotid gland. MATERIALS AND METHODS. Forty-nine patients with increased FDG uptake in the parotid gland were selected for the study group (29 men and 20 women; mean age, 63.14 ± 12.32 years). Another 49 patients without head and neck malignancies were selected as the control group (24 men and 25 women; mean age, 65.80 ± 11.51 years); they did not have a parotid lesion or increased FDG uptake in the parotid gland. Maximum standardized uptake value (SUV max) was obtained for all patients. Metabolic tumor volume and total glycolytic activity were measured in patients with a discrete parotid lesion (n = 24). Nonparameteric Student t test (Mann- Whitney U test) was performed for between-group analysis. RESULTS. The median SUV max of the increased diffuse uptake (2.55; interquartile range [IQR], 1.03-4.07) was significantly lower than the median SUV max of tumors (8.48; IQR, 1.46-15.5) (p < 0.01). The median SUV max of malignant tumors (11.8; IQR, 4.45-19.15) was significantly (p < 0.05) higher than that of benign tumors (6.4; IQR, 3.4-9.0). There was significant difference (p = 0.003) in the median metabolic tumor volume for malignant tumors (8.9; IQR, 5.1-25.5) and benign tumors or lesions (1.4; IQR, 1.00-2.9). Similar results were found for total glycolytic activity for malignant tumors (67.9; IQR, 24.2-137.6) and benign tumors or lesions (8.4; IQR, 3.9-13.6) (p = 0.002). CONCLUSION. FDG PET/CT SUV max, metabolic tumor volume, and total glycolytic activity are imaging parameters to differentiate benign and malignant tumors of the parotid gland.

AB - OBJECTIVE. The purpose of this article is to establish 18F-FDG metabolic imaging parameters to differentiate benign and malignant tumors of the parotid gland. MATERIALS AND METHODS. Forty-nine patients with increased FDG uptake in the parotid gland were selected for the study group (29 men and 20 women; mean age, 63.14 ± 12.32 years). Another 49 patients without head and neck malignancies were selected as the control group (24 men and 25 women; mean age, 65.80 ± 11.51 years); they did not have a parotid lesion or increased FDG uptake in the parotid gland. Maximum standardized uptake value (SUV max) was obtained for all patients. Metabolic tumor volume and total glycolytic activity were measured in patients with a discrete parotid lesion (n = 24). Nonparameteric Student t test (Mann- Whitney U test) was performed for between-group analysis. RESULTS. The median SUV max of the increased diffuse uptake (2.55; interquartile range [IQR], 1.03-4.07) was significantly lower than the median SUV max of tumors (8.48; IQR, 1.46-15.5) (p < 0.01). The median SUV max of malignant tumors (11.8; IQR, 4.45-19.15) was significantly (p < 0.05) higher than that of benign tumors (6.4; IQR, 3.4-9.0). There was significant difference (p = 0.003) in the median metabolic tumor volume for malignant tumors (8.9; IQR, 5.1-25.5) and benign tumors or lesions (1.4; IQR, 1.00-2.9). Similar results were found for total glycolytic activity for malignant tumors (67.9; IQR, 24.2-137.6) and benign tumors or lesions (8.4; IQR, 3.9-13.6) (p = 0.002). CONCLUSION. FDG PET/CT SUV max, metabolic tumor volume, and total glycolytic activity are imaging parameters to differentiate benign and malignant tumors of the parotid gland.

KW - FDG

KW - Metabolic tumor volume

KW - Parotid gland

KW - Tumors

UR - http://www.scopus.com/inward/record.url?scp=84856084725&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856084725&partnerID=8YFLogxK

U2 - 10.2214/AJR.11.7172

DO - 10.2214/AJR.11.7172

M3 - Article

C2 - 22268210

AN - SCOPUS:84856084725

VL - 198

JO - American Journal of Roentgenology

JF - American Journal of Roentgenology

SN - 0361-803X

IS - 2

ER -